Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Omeprazole on Tepotinib PK in Healthy Subjects
NCT03531762Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- May 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tepotinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration at Day 5, Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity at Day 5 and 1 more. Started May 2018; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03531762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531762.